AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.
Source:: Reuters – Business News
Newswire
- [ July 17, 2026 ] Fastly (NASDAQ: FSLY) Stock Analysis: Edge Platform Reaches an Inflection Point Arena Signals
- [ July 17, 2026 ] Innoviz Technologies (NASDAQ: INVZ) Stock Analysis: Building the Perception Layer for the Physical AI Revolution Arena Signals
- [ July 17, 2026 ] Neuronetics (NASDAQ: STIM) Stock Analysis: Building an Integrated Mental Health Treatment Platform Arena Signals
- [ July 16, 2026 ] AST SpaceMobile (NASDAQ: ASTS) Stock Analysis: Building World’s First Space-Based Broadband Provider Arena Signals
- [ July 14, 2026 ] GameStop (NYSE: GME) Stock Analysis: Profitable Turnaround — Is Ryan Cohen This Generation’s Warren Buffett? Arena Signals
- [ July 14, 2026 ] Quantum (NASDAQ: QMCO) Stock Analysis: Rebuilding the Data Infrastructure Company for the AI Era Arena Signals
- [ July 14, 2026 ] Expensify (NASDAQ: EXFY) Stock Analysis: Building the AI-Native Financial Superapp for Business Spending Arena Signals
- [ July 14, 2026 ] 3D Systems (NYSE: DDD) Stock Analysis: “Med tech, dental, and aerospace and defense, are rapidly adopting 3D printing as a core manufacturing method.” Arena Signals
- [ July 14, 2026 ] PagerDuty (NYSE: PD) Stock Analysis: Becoming the AI Control Plane for Enterprise Operations Arena Signals
- [ July 14, 2026 ] Xometry (NASDAQ: XMTR) Stock Analysis: Building the AI-Native Operating System for Global Manufacturing Arena Signals
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.